Two documents summarize the main messages of the ESC 2017 STEMI management guidelines, namely changes with respect to the 2012 version and ‘ten commandments’ to follow.
AHA 2017 The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.
Using a case description and study data, dr. Jur ten Berg explains how management of these ACS patients differs from patients who are not anticoagulated with NOACs.
ESC 2017 Fewer major bleedings with dual therapy of dabigatran and platelet inhibitor than with triple therapy with warfarin, platelet inhibitor and aspirin, in AF patients receiving a stent in RE-DUAL PCI..
ESC 2017 PEGASUS substudy shows that continued treatment with ticagrelor within 2 years after MI or 1 year after stopping ADP receptor inhibition, reduces CV death in patients at high atherothrombotic risk.
ESC 2017 One of the Grand Debates of course focused on different interpretations of the CANTOS trial data. Paul Ridker and Alberico Catapano debated how central inflammation is to CVD.
Mendelian analysis confirms a causal relationship of both central and general adiposity with the risk of CHD and T2DM, whereas central adiposity was stronger linked to ischemic stroke.
Strong association between elevated plasma apo CIII levels with CAD risk may be due to elevated levels of remnant lipoproteins, small dense LDL and low-grade inflammation.
LDL-C levels <30 mg/dL at 1 month were associated with a similar safety profile and with numerical reductions in CV events compared with higher LDL-C levels in high-risk post-ACS patients.
ACC 2017 A safety study of rivaroxaban versus aspirin on top of P2Y12 therapy in ACS patients, showed that this dual antithrombotic regimen had a similar risk of clinically significant bleeding.
In diabetic post-ACS patients, the magnitude of high sensitivity troponin I elevation was an independent predictor of ischemic and heart failure events.
Pioglitazone reduced the risk of acute coronary syndrome events, particularly type 2 MIs, in insulin resistant patients without diabetes but with a history of stroke or TIA.